Related Experiment Video

Updated: Jan 11, 2026

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.3K

Population Pharmacokinetics Model and Simulation of Unbound and Total Valproic Acid in Epileptic Children Using a

Tingting Yue1, Limei Zhao2, Ya'nan Chen3

  • 1Department of Neurosurgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Basic & Clinical Pharmacology & Toxicology
|November 17, 2025
PubMed

Insights

A population pharmacokinetic model for valproic acid (VPA) in children was developed. This model helps optimize VPA dosing regimens for pediatric epilepsy, ensuring effective treatment within its narrow therapeutic window.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Pediatric Neurology

Background:

  • Valproic acid (VPA) is a key antiepileptic drug in pediatric epilepsy.
  • Its efficacy is linked to the unbound fraction, necessitating precise dosing.
  • VPA has a narrow therapeutic window, increasing risks with suboptimal concentrations.

Purpose of the Study:

  • To develop a population pharmacokinetic (PopPK) model for unbound and total VPA in children.
  • To establish an optimized dosing strategy for pediatric epilepsy treatment.
  • To simulate and propose VPA dosage regimens for improved clinical outcomes.

Main Methods:

  • Developed a one-compartment PopPK model for unbound VPA.
  • Utilized 620 samples from 450 pediatric epilepsy patients.
  • Employed the Langmuir equation to analyze protein binding and Monte Carlo simulations for dose regimen proposals.

Main Results:

  • The model identified body weight, age-related maturation, and daily dose as significant factors influencing VPA clearance.
  • Simulations recommended VPA dosages of 10-30 mg/kg/day for children aged 0-12 years, adjusted for age.
  • The model accurately described VPA pharmacokinetics in the pediatric population.

Conclusions:

  • The developed VPA PopPK model provides a valuable tool for optimizing pediatric epilepsy treatment.
  • It facilitates the proposal of precise dosage regimens to maintain VPA within the target therapeutic window.
  • This approach supports safer and more effective VPA therapy in children.

Keywords:
epileptic childrenpopulation pharmacokineticsprotein bindingtherapeutic drug monitoringvalproic acid

More Related Videos

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.3K
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

6.2K

Related Concept Videos

Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
204
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
569
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.3K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
249
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
257
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.8K